Baumann Oliver Rolf

SEC Form 4 insider trading activity

Baumann Oliver Rolf has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Aug 31, 2026.

On the most recent filing, Baumann Oliver Rolf is listed as Director at Veraxa Biotech AG - Post de-SPAC. Inside the rolling window, Baumann Oliver Rolf reported 1 open-market purchase totaling $75K in VRXA and no open-market sales.

Companies traded

Other insiders at VRXA

Insider Buying

$75K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
VRXA
Baumann Oliver Rolf
Purchase$75KAug 31SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Baumann Oliver Rolf made?

Baumann Oliver Rolf has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.

Which companies does Baumann Oliver Rolf trade?

Baumann Oliver Rolf has filed SEC Form 4 disclosures for 1 company, including VRXA.

When was Baumann Oliver Rolf's most recent SEC Form 4 filing?

Baumann Oliver Rolf's most recent SEC Form 4 filing on Tracefour is dated Aug 31, 2026.

What is Baumann Oliver Rolf's total buy and sell value in the current window?

Inside the rolling retention window, Baumann Oliver Rolf bought $75K and sold $0 based on SEC Form 4 filings.

What was Baumann Oliver Rolf's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 50,000 VRXA shares on 2026-08-27, worth $75K, per SEC Form 4 filings.